Heart disease is a major cause of hospitalization, reduced quality of life, and shortened survival in people with kidney disease. We will develop tools to help doctors share personalized information with patients on the benefits versus risks of having a heart procedure, and help patients better communicate their own values and preferences.
We will test the Kidney Failure Risk equation via interactive tools in family medicine clinics across Canada. The interactive tools will help patients and their doctors gain a better understanding of their kidney health and will help guide their care.
Defining risk and personalizing treatment of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)admin2018-08-01T16:26:40-07:00
Genetic screening and tests of kidney size can help nephrologists identify high-risk patients for new or experimental treatments, moderate-risk patients for close surveillance, and low-risk patients for reassurance. These tests, however, are costly and not widely available. We will confirm the usefulness of these tests and make them less costly, allowing for increased use in clinics.
Using mobile lab equipment, screening teams will travel to communities and test for CKD and its risk factors, including diabetes and high blood pressure. This information will be used to determine an individual’s risk of CKD, and each person will receive a treatment plan that is tailored to their risk.
AdDIT is studying an observational cohort of youth with type 1 diabetes along with a group of healthy age-matched subjects and longitudinally assessing both kidney function and cardiovascular function.
The AdDIT (Adolescent Diabetes Cardio-Renal Intervention Trial) and iCARE (Improving Renal Complications in Adolescents with Type 2 Diabetes through Research) studies are working together to identify the most important risk factors for early kidney disease in youth with diabetes.